Learning & Development Asia 2024
WuXi AppTec's new Singapore site expected to generate about 1,600 jobs once operational from 2027

WuXi AppTec's new Singapore site expected to generate about 1,600 jobs once operational from 2027

The new 50-acre site is located in Tuas Biomedical Park.

WuXi AppTec, which provies R&D and manufacturing services for companies in the pharmaceutical and life science sectors, has announced the groundbreaking of its new R&D and manufacturing site in Singapore on 23 May 2024 (Thursday). 

According to a press release issued by EDB, the new 50-acre site in Singapore is situated in Tuas Biomedical Park.

Developed and master-planned by JTC, this site will eventually house seven plants. Once fully operational, it will offer R&D and manufacturing services for active pharmaceutical ingredients (APIs), including small molecules, oligonucleotides, peptides, and complex synthetic conjugates.

The site is expected to be built in phases, and projected to start operations in 2027. Approximately 1,600 employment opportunities are aimed to be created once the site is fully built.

The new site embraces green chemistry technologies to enhance industrial practices and support local sustainable development. 

Per the statement, the Singapore site will work closely with existing locations in Asia, Europe, and North America and will provide effective CRDMO (contract research development & manufacturing organisation) solutions for drug R&D from discovery to commercialisation, with increased flexibility and scalability.

At the groundbreaking ceremony, Dr. Ge Li, Chairman and CEO, WuXi AppTec said: "With the enhanced capacity and capabilities, we are building at this new Singapore site, we look forward to continuing to help our customers accelerate the development and commercialisation of life-saving treatments and medicines for patients around the world."

Png Cheong Boon, Chairman, EDB shared: "With R&D and manufacturing activities housed under one roof, WuXi AppTec will be building a sizeable local team to drive the development of innovative therapeutics in Singapore to serve patients globally."

Dr. Minzhang Chen, Co-CEO, WuXi AppTec added: "We are thrilled to break ground on our long-planned site in Singapore. 

"The progress we’ve made with many of our local partners is remarkable." 


READ MORE: Uhlmann Pac-Systeme opens new office in Singapore 

Lead image / EDB

Follow us on Telegram and on Instagram @humanresourcesonline for all the latest HR and manpower news from around the region!

Free newsletter

Get the daily lowdown on Asia's top Human Resources stories.

We break down the big and messy topics of the day so you're updated on the most important developments in Asia's Human Resources development – for free.

subscribe now open in new window